Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis

The Lancet Infectious Diseases

Volumn 17, Issue 8, 2017, Pages 873-881

  Rajasingham, Radha ^a   Smith, Rachel M ^b   Park, Benjamin J ^b   Jarvis, Joseph N ^c,d,e,f   Govender, Nelesh P ^g,h,i   Chiller, Tom M ^b   Denning, David W ^j   Loyse, Angela ^k   Boulware, David R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d BOTSWANA UPENN PARTNERSHIP   (Botswana)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^g NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^h UNIVERSITY OF CAPE TOWN   (South Africa)

ⁱ UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

^k ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AFRICA SOUTH OF THE SAHARA; ANTIRETROVIRAL THERAPY; ARTICLE; ASIA; CARIBBEAN; CD4 LYMPHOCYTE COUNT; CRYPTOCOCCAL MENINGITIS; EUROPE; FOLLOW UP; GLOBAL DISEASE BURDEN; HIGH INCOME COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LOW INCOME COUNTRY; MAJOR CLINICAL STUDY; MIDDLE EAST; MIDDLE INCOME COUNTRY; NORTH AFRICA; NORTH AMERICA; PACIFIC ISLANDS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; TREATMENT FAILURE; WORLD HEALTH ORGANIZATION; ADOLESCENT; AGED; BLOOD; COMPLICATION; FEMALE; GLOBAL HEALTH; HIV INFECTIONS; INCIDENCE; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ANTIRETROVIRUS AGENT; FUNGUS ANTIGEN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-RETROVIRAL AGENTS; ANTIGENS, FUNGAL; CD4 LYMPHOCYTE COUNT; FEMALE; GLOBAL BURDEN OF DISEASE; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; INCIDENCE; LOST TO FOLLOW-UP; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PREVALENCE; SURVIVAL ANALYSIS; TREATMENT FAILURE; YOUNG ADULT;

EID: 85018786822     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30243-8     Document Type: Article

References (67)

1. Durski, KN, Kuntz, KM, Yasukawa, K, Virnig, BA, Meya, DB, Boulware, DR, Cost-effective diagnostic checklists for meningitis in resource-limited settings. J Acquir Immune Defic Syndr 63 (2013), e101–e108.
2. Jarvis, JN, Meintjes, G, Williams, A, Brown, Y, Crede, T, Harrison, TS, Adult meningitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect Dis, 10, 2010, 67.
3. Siddiqi, OK, Ghebremichael, M, Dang, X, et al. Molecular diagnosis of central nervous system opportunistic infections in HIV-infected Zambian adults. Clin Infect Dis 58 (2014), 1771–1777.
4. Jarvis, JN, Boulle, A, Loyse, A, et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 23 (2009), 1182–1223.
5. National Institute for Communicable Diseases. GERMS-South Africa Annual Report 2015. http://www.nicd.ac.za/?page=publications&id=196 (accessed Oct 25, 2016).
6. Mirza, SA, Phelan, M, Rimland, D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992–2000. Clin Infect Dis 36 (2003), 789–794.
7. Wall, EC, Everett, DB, Mukaka, M, et al. Bacterial meningitis in Malawian adults, adolescents, and children during the era of antiretroviral scale-up and Haemophilus influenzae type b vaccination, 2000–2012. Clin Infect Dis 58 (2014), e137–e145.
8. Park, BJ, Wannemuehler, KA, Marston, BJ, Govender, N, Pappas, PG, Chiller, TM, Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 23 (2009), 525–530.
9. UNAIDS. Gap report, fact sheet. http://www.unaids.org/en/resources/campaigns/2014gapreport, 2014 (Dec 21, 2014).
10. Meya, DB, Manabe, YC, Castelnuovo, B, et al. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis 51 (2010), 448–455.
11. Jarvis, JN, Lawn, SD, Vogt, M, Bangani, N, Wood, R, Harrison, TS, Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 48 (2009), 856–862.
12. Letang, E, Muller, MC, Ntamatungiro, AJ, et al. Cryptococcal antigenemia in immunocompromised HIV patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis, 2, 2015, ofv046.
13. McKenney, J, Bauman, S, Neary, B, et al. Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986–2012. Clin Infect Dis 60 (2015), 959–965.
14. WHO. Rapid advice: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children. http://www.who.int/hiv/pub/cryptococcal_disease2011 (accessed Nov 1, 2015).
15. PEPFAR. The President's Emergency Plan for AIDS Relief: FY 2013 technical considerations. http://www.pepfar.gov/documents/organization/199147.pdf (accessed Oct 25, 2016).
16. Masur, H, Brooks, JT, Benson, CA, Holmes, KK, Pau, AK, Kaplan, JE, Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 58 (2014), 1308–1311.
17. Mfinanga, S, Chanda, D, Kivuyo, SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385 (2015), 2173–2182.
18. Jarvis, JN, Harrison, TS, Lawn, SD, Meintjes, G, Wood, R, Cleary, S, Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa. PLOS One, 8, 2013, e69288.
19. UNAIDS. Access to antiretroviral therapy in Africa: status report on progress towards the 2015 targets. 2013 Geneva. http://www.unaids.org/en/resources/documents/2013 (accessed Oct 25, 2016).
20. Avila, D, Althoff, KN, Mugglin, C, et al. Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-, and high-income countries. J Acquir Immune Defic Syndr 65 (2014), e8–e16.
21. Mocroft, A, Lundgren, J, Antinori, A, for the Late presenters working group in COHERE in EuroCoord. Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill, 20, 2015, 47.
22. European Centre for Disease Prevention and Control, WHO Regional Office for Europe. HIV/AIDS Surveillance in Europe. http://ecdc.europa.eu/en/healthtopics/aids/surveillance-reports/Pages/surveillance-reports.aspx, 2014 (accessed Dec 1, 2015).
23. Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas—2013. HIV Surveill Suppl Rep, 20, 2015, 2.
24. UNAIDS. Spectrum. http://www.unaids.org/en/dataanalysis/datatools/spectrumepp (accessed Nov 1, 2015).
25. UNAIDS 2015: AIDS by the numbers. http://www.unaids.org/en/resources/documents/2015/AIDS_by_the_numbers_2015 (accessed Nov 25, 2016).
26. McMahon, JH, Elliott, JH, Bertagnolio, S, Kubiak, R, Jordan, MR, Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review. Bull World Health Organ 91 (2013), 377–385.
27. Castelnuovo, B, Kiragga, A, Mubiru, F, Kambugu, A, Kamya, M, Reynolds, SJ, First-line antiretroviral therapy durability in a 10-year cohort of naive adults started on treatment in Uganda. J Int AIDS Soc, 19, 2016, 20773.
28. Castelnuovo, B, Kiragga, A, Musaazi, J, et al. Outcomes in a cohort of patients started on antiretroviral treatment and followed up for a decade in an urban clinic in Uganda. PLOS One, 10, 2015, e0142722.
29. Sanne, IM, Westreich, D, Macphail, AP, Rubel, D, Majuba, P, Van Rie, A, Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc, 12, 2009, 38.
30. Parkes-Ratanshi, R, Wakeham, K, Levin, J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial. Lancet Infect Dis 11 (2011), 933–941.
31. Govender, N, Roy, M, Mendes, J, Zulu, T, Chiller, T, Karstaedt, A, Evaluation of screening and treatment of cryptococcal antigenaemia among HIV-infected persons in Soweto, South Africa. HIV Med 16 (2015), 468–476.
32. Pongsai, P, Atamasirikul, K, Sungkanuparph, S, The role of serum cryptococcal antigen screening for the early diagnosis of cryptococcosis in HIV-infected patients with different ranges of CD4 cell counts. J Infect 60 (2010), 474–477.
33. Butler, EK, Boulware, DR, Bohjanen, PR, Meya, DB, Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda. PLOS One, 7, 2012, e51291.
34. Jarvis, JN, Bicanic, T, Loyse, A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis 58 (2014), 736–745.
35. Gaskell, KM, Rothe, C, Gnanadurai, R, et al. A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi. PLOS One, 9, 2014, e110285.
36. Lessells, RJ, Mutevedzi, PC, Heller, T, Newell, ML, Poor long-term outcomes for cryptococcal meningitis in rural South Africa. South African Med J 101 (2011), 251–252.
37. Baldassarre, R, Mdodo, R, Omonge, E, et al. Mortality after clinical management of aids-associated cryptococcal meningitis in Kenya. East African Med J 91 (2014), 145–151.
38. Rothe, C, Sloan, DJ, Goodson, P, et al. A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. PLOS One, 8, 2013, e67311.
39. Kendi, C, Penner, J, Koech, J, et al. Predictors of outcome in routine care for cryptococcal meningitis in Western Kenya: lessons for HIV outpatient care in resource-limited settings. Postgrad Med J 89 (2013), 73–77.
40. Rajasingham, R, Rolfes, MA, Birkenkamp, KE, Meya, DB, Boulware, DR, Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis. PLoS Med, 9, 2012, e1001316.
41. Vidal, JE, Penalva de Oliveira, AC, Dauar, RF, Boulware, DR, Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin America. Braz J Infect Dis 17 (2013), 353–362.
42. Jongwutiwes, U, Kiertiburanakul, S, Sungkanuparph, S, Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 5 (2007), 355–360.
43. Pyrgos, V, Seitz, AE, Steiner, CA, Prevots, DR, Williamson, PR, Epidemiology of cryptococcal meningitis in the US: 1997–2009. PLOS One, 8, 2013, e56269.
44. Lortholary, O, Poizat, G, Zeller, V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 20 (2006), 2183–2191.
45. Mwaba, P, Mwansa, J, Chintu, C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 77 (2001), 769–773.
46. WHO. Global Health Observatory (GHO) data. http://www.who.int/gho/en, 2015 (accessed Nov 1, 2015).
47. Bansi, L, Sabin, C, Gilson, R, et al. Virological response to initial antiretroviral regimens containing abacavir or tenofovir. J Infect Dis 200 (2009), 710–714.
48. Uy, J, Armon, C, Buchacz, K, Wood, K, Brooks, JT, Initiation of HAART at higher CD4 cell counts is associated with a lower frequency of antiretroviral drug resistance mutations at virologic failure. J Acquir Immune Defic Syndr 51 (2009), 450–453.
49. Moore, DM, Mermin, J, Awor, A, Yip, B, Hogg, RS, Montaner, JS, Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings. J Acquir Immune Defic Syndr 43 (2006), 436–439.
50. Mayanja-Kizza, H, Oishi, K, Mitarai, S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 26 (1998), 1362–1366.
51. Letang, E, Muller, MC, Ntamatungiro, AJ, et al. Cryptococcal antigenemia in immunocompromised HIV patients in rural Tanzania: a preventable cause of early mortality. Open Forum Infect Dis, 2, 2015, ofv046.
52. Mfinanga, S, Chanda, D, Kivuyo, SL, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet 385 (2015), 2173–2182.
53. Joint Medical Store. Product catalogue. http://www.jms.co.ug/sites/default/files/resources/Current%20Price%20Catalogue.pdf (accessed Oct 25, 2016).
54. Rajasingham, R, Meya, DB, Boulware, DR, Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J Acquir Immune Defic Syndr 59 (2012), e85–e91.
55. National Health Laboratory Service. National Health Laboratory Services annual report 2015/2016. http://www.nhls.ac.za/?page=annual_report&id=45 (accessed Oct 15, 2016).
56. Morawski BM, Boulware DR, Nalintya E, et al. Pre-ART cryptococcal antigen titer associated with preemptive fluconazole failure. Conference on Retroviruses and Opportunistic Infections; Boston, MA; Feb 22–25, 2016. Abstract 159.
57. Lozano, R, Naghavi, M, Foreman, K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2095–2128.
58. Castelnuovo, B, Manabe, YC, Kiragga, A, Kamya, M, Easterbrook, P, Kambugu, A, Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis 49 (2009), 965–972.
59. French, N, Gray, K, Watera, C, et al. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 16 (2002), 1031–1038.
60. Liechty, CA, Solberg, P, Were, W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 12 (2007), 929–935.
61. Lawn, SD, Bekker, LG, Myer, L, Orrell, C, Wood, R, Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 19 (2005), 2050–2052.
62. Lawn, SD, Harries, AD, Anglaret, X, Myer, L, Wood, R, Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22 (2008), 1897–1908.
63. Rajasingham, R, Boulware, DR, Reconsidering cryptococcal antigen screening in the US among persons with CD4 <100 cells/mcL. Clin Infect Dis 55 (2012), 1742–1744.
64. UNAIDS 2016 Prevention Gap Report. http://www.unaids.org/en/resources/documents/2016/prevention-gap (accessed Feb 1, 2017).
65. Siedner, MJ, Ng, CK, Bassett, IV, Katz, IT, Bangsberg, DR, Tsai, AC, Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002–2013: a meta-analysis. Clin Infect Dis 60 (2015), 1120–1127.
66. Lahuerta, M, Wu, Y, Hoffman, S, et al. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006–2011: findings from four sub-saharan African countries. Clin Infect Dis 58 (2014), 432–441.
67. Resch, S, Ryckman, T, Hecht, R, Funding AIDS programmes in the era of shared responsibility: an analysis of domestic spending in 12 low-income and middle-income countries. Lancet Glob Health 3 (2015), e52–e61.